Literature DB >> 16014142

Fate of the unligated vertical vein after repair of supracardiac anomalous pulmonary venous connection.

Y F Cheung1, K S Lun, Adolphus K T Chau, Clement S W Chiu.   

Abstract

OBJECTIVE: To determine the fate of the unligated vertical vein after repair of isolated supracardiac total anomalous pulmonary venous connection (TAPVC).
METHODS: We reviewed the outcome of 28 patients who were diagnosed to have isolated supracardiac TAPVC and determined the fate of the unligated vertical vein.
RESULTS: Of the 28 patients, four died before surgery. The remaining 24 patients underwent surgical correction of TAPVC with (n = 5) or without (n = 19) ligation of vertical vein at a median age of 20 days (range: 1-574 days). There were no significant differences in age, weight, presence of pulmonary venous obstruction, need for preoperative inotropic and ventilatory support, cardiopulmonary bypass duration, postoperative pulmonary hypertensive crisis and requirement of peritoneal dialysis between patients with and those without vertical vein ligation. The in-hospital surgical mortality was 50% (12/24), with 83% (10/12) of deaths occurring before 1990. Patients who died after surgery were significantly younger (median age: 5.5 days vs 37 days, P = 0.005), lighter (3.3 +/- 0.5 kg vs 3.9 +/- 0.6 kg, P = 0.016), more likely to have pulmonary venous obstruction preoperatively (75% vs 12%, P = 0.039) and have undergone surgery before 1990 (83% vs 33%, P = 0.036). The 12 survivors were followed up for a median of 4.7 years (range: 2.3-18.1 years), 10 of whom had their vertical vein unligated. The vertical vein remained patent in five (50%) patients, while stenosis of pulmonary venous anastomosis was only present in one patient. Of these five patients, three had subsequently undergone surgical ligation of the vertical vein to eliminate a large left-to-right shunt.
CONCLUSIONS: Patency of the unligated vertical vein is common after the repair of supracardiac TAPVC, even in the absence of pulmonary venous obstruction. The degree of left-to-right shunt through the patent vertical vein may be so significant as to warrant surgical ligation.

Entities:  

Mesh:

Year:  2005        PMID: 16014142     DOI: 10.1111/j.1440-1754.2005.00632.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  6 in total

1.  Percutaneous closure of a large unligated vertical vein using the Amplatzer Vascular Plug II after supracardiac total anomalous pulmonary venous connection (TAPVC) repair.

Authors:  Vimalarani Devendran; Neil Wilson; Vimala Jesudian
Journal:  Pediatr Cardiol       Date:  2012-09-28       Impact factor: 1.655

2.  Factors Associated with Early Postoperative Results of Total Anomalous Pulmonary Venous Connection Repair: Findings from Retrospective Single-Institution Data in Vietnam.

Authors:  Doan Quoc Hung; Dinh Xuan Huy; Hoang-Long Vo; Nguyen Sinh Hien
Journal:  Integr Blood Press Control       Date:  2021-06-01

3.  Transcatheter Closure of Partially Ligated Vertical Vein after Surgical Correction of Supracardiac Total Anomalous Pulmonary Venous Connection.

Authors:  Hamid Amoozgar; Maryam Ahmadipoor; Ahmad Ali Amirghofran
Journal:  J Tehran Heart Cent       Date:  2015-07-03

4.  Dual pathology causing severe pulmonary hypertension following surgical repair of total anomalous pulmonary venous connection: Successful outcome following serial transcatheter interventions.

Authors:  Shreepal Jain; Neeta S Bachani; Robin J Pinto; Bharat V Dalvi
Journal:  Ann Pediatr Cardiol       Date:  2018 Jan-Apr

5.  Transcatheter closure of patent vertical vein after repair of total anomalous pulmonary venous connection.

Authors:  Sudeep Verma; Anand Subramanian; Rajan Saileela; Nageswara Rao Koneti
Journal:  Ann Pediatr Cardiol       Date:  2015 Sep-Dec

6.  Catheter closure of a recanalized vertical vein after repair of total anomalous pulmonary venous connection.

Authors:  Ramy Charbel; Najib Hanna; Linda Daou; Zakhia Saliba
Journal:  Clin Case Rep       Date:  2018-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.